Answers are grounded in this paper and cite their sources.
Hereditary angioedema (HAE) is a severe inherited disease characterized by unpredictable, recurrent swelling episodes driven by excessive bradykinin generation. As advances in structural biology and targeted therapeutic modalities have accumulated, HAE management has evolved from symptomatic suppression to mechanism-based intervention, with current clinical strategies anchored in C1-INH replacement, plasma kallikrein inhibition, factor XIIa blockade, and bradykinin B2 receptor antagonism. In this review, we provide a drug-discovery perspective on the development of therapeutics targeting these validated targets. We summarize the major therapeutic modalities, including monoclonal antibodies, peptides, orally available small molecules, and nucleic-acid-based therapeutics, as well as strategies for developing long-acting formulations. We also highlight how advances in structural biology, chemical-space exploration, and developability optimization have guided the design and development of these therapeutics. Furthermore, we discuss potential targets beyond the canonical pathway, including contact-system amplification nodes, bypass or noncanonical routes to bradykinin generation, and endothelial barrier regulators, which may inform precision or combination strategies. Together, these perspectives broaden the therapeutic landscape and provide a rationale for the development of next-generation HAE therapies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: